-
CVS Stock Trades Higher Following Guidance Hike: What Investors Need To Know
Thursday, December 9, 2021 - 12:48pm | 329Read More...CVS Health Corp (NYSE: CVS) shares traded higher Thursday after the company raised its fiscal 2022 financial guidance ahead of its upcoming investor day event. One analyst said the new outlook is encouraging for CVS investors, and the company has plenty of momentum heading into 2022. The CVS...
-
Why This Hims Analyst Sees Strong Growth Potential In Highly Competitive Market
Tuesday, July 6, 2021 - 1:15pm | 290Read More...The potential for expansion coupled with a highly competitive pharmacy market has a BofA Securities analyst sidelined on shares of Hims & Hers Health, Inc. (NYSE: HIMS). The Hims Analyst: Michael Cherny initiated coverage on shares of Hims & Hers Health, Inc. with a Neutral rating and...
-
Why BofA Is Double Downgrading Cerner: 'Not Much Room For Upside'
Tuesday, January 19, 2021 - 1:09pm | 286Read More...Cerner Corporation’s (NASDAQ: CERN) long-term growth is likely to be slightly lower than was earlier anticipated, and there is lack of a “possible novel catalyst” to drive share price appreciation, according to BofA Securities. The Cerner Analyst: Michael Cherny downgraded Cerner...
-
BofA Cuts Walgreens Earnings Estimate, Says Visibility Limited On Pharmacy Chain's Growth
Wednesday, August 26, 2020 - 12:30pm | 541Read More...Walgreens Boots Alliance Inc (NASDAQ: WBA) has struggled in 2020, but its problems started well before the COVID-19 economic disruption. The stock is now down 52.3% over the last five years, and BofA Securities analyst Michael Cherny said Wednesday there’s little reason to expect...
-
Analyst Breaks Down CVS Health's 'Complicated' Quarter
Tuesday, August 11, 2020 - 1:31pm | 453Read More...CVS Health Corp's (NYSE: CVS) second-quarter earnings report can be defined as "more good than bad" yet the stock still trades at a discounted valuation, according to BofA Securities. The CVS Analyst: Michael Cherny maintains a Buy rating on CVS with an $80 price target. The...
-
These Analysts Like HealthEquity's Post-Q3 Story
Wednesday, December 4, 2019 - 10:28am | 765Read More...HealthEquity Inc (NASDAQ: HQY) outperformed third-quarter expectations with a 47-cent bottom-line more than double analyst forecasts. Revenue of $157.1 million also beat consensus estimates of $152.4 million, while EBITDA closed the quarter at $56 million against $43 million forecasts....
-
BofA Expects Dentsply Sirona's Performance To Improve With New Product Ramp, Cost-Cutting
Monday, March 18, 2019 - 12:51pm | 302Read More...Dentsply Sirona Inc (NASDAQ: XRAY) is in the midst of a major transition. Potential cost savings should support EPS, and the dental equipment supplier could achieve more consistent revenue growth due to new product launches and a slight improvement in the dental market, according to Bank of America...
-
Patterson Shares Downgraded To Sell At UBS
Tuesday, July 11, 2017 - 12:23pm | 379Read More...Analysts at UBS turned bearish on Patterson Companies, Inc. (NASDAQ: PDCO) as the company's exclusive relationship with Sirona will come to an end in September. UBS's Michael Cherny downgrades Patterson's stock rating from Neutral to Sell with a price target slashed from $44.50 to $40 as the...
-
UPDATE: ISI Group Downgrades MedAssets Following Earnings Results
Thursday, October 31, 2013 - 10:08am | 248Read More...In a report published Thursday, ISI Group analyst Michael Cherny downgraded the rating on MedAssets (NASDAQ: MDAS) from Neutral to Buy, and lowered the price target from $28.00 to $26.00. In the report, ISI Group noted, “We are downgrading MDAS from Buy to Neutral post [yesterday] afternoon's...
-
ISI Upgraded McKesson Following Celesio Aquisition and Strong FY2Q14 Results
Thursday, October 24, 2013 - 2:37pm | 323Read More...In a report published Thursday, ISI Group LLC analyst Michael Cherny upgraded McKesson Corporation (NYSE: MCK) from Buy to Strong Buy, raising estimates and the PT from $152 to $175 following the Celesio acquisition and strong FY2Q14 results. This morning, McKesson announced that they are...
-
UPDATE: ISI Group Downgrades Allscripts Healthcare Solutions Following Recent Outperformance
Monday, July 15, 2013 - 8:19am | 248Read More...In a report published Monday, ISI Group analyst Michael Cherny downgraded the rating on Allscripts Healthcare Solutions (NASDAQ: MDRX) from Buy to Neutral, but raised the price target from $15.50 to $16.50. In the report, ISI Group noted, “We have downgraded our rating on MDRX from Buy to...
-
UPDATE: ISI Group Upgrades Patterson Companies Following National Veterinary Services Acquisition
Monday, July 15, 2013 - 8:13am | 243Read More...In a report published Monday, ISI Group analyst Michael Cherny upgraded the rating on Patterson Companies (NASDAQ: PDCO) from Cautious to Neutral, and raised the price target from $36.50 to $39.50. In the report, ISI Group noted, “Ahead of FY1Q earnings and following the acquisition National...
-
UPDATE: ISI Group Upgrades Catamaran Following Recent Pullback
Monday, July 15, 2013 - 8:11am | 259Read More...In a report published Monday, ISI Group analyst Michael Cherny upgraded the rating on Catamaran (NASDAQ: CTRX) from Buy to Strong Buy, but lowered the price target from $68.00 to $62.00. In the report, ISI Group noted, “We are upgrading CTRX from Buy to Strong Buy following the recent pullback...
-
Medco Poised For Bright Future, Says Deutsche Bank (MHS)
Tuesday, June 29, 2010 - 9:23am | 121Read More...Deutsche Bank analysts Ross Muken, Michael Cherny, and Vijay Kumar reiterated a Buy rating and %78 price target for Medco (NYSE: MHS). The analysts see sustained growth at Medco, driven by several drivers, including growth in generics, mail, and PGx. They said, "While there is some debate on the...
-
MedcoHealth Solutions (MHS) Announces $3 Billion Buyback
Thursday, May 13, 2010 - 2:01pm | 206Read More...Deutsche Bank Securities analysts Ross Muken, Michael Cherny and Vijay Kumar reiterated their Buy rating for shares of MedcoHealth Solutions Inc (NYSE: MHS), with a price target of $78 per share. The analysts reiterated their Buy rating for MedcoHealth Solutions Inc after the company's board of...
